Acadia Pharmaceuticals (ACAD) Assets (2010 - 2026)

Acadia Pharmaceuticals' Assets history runs 17 years deep, the most recent figure standing at $1.6 billion for Q1 2026.

• On a quarterly basis, Assets rose 41.76% year-over-year to $1.6 billion in Q1 2026; TTM through Mar 2026 was $1.6 billion, a 41.76% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 31.69% from the prior year.
• Assets grew to $1.6 billion in Q1 2026 per ACAD's latest filing, from $1.6 billion in the prior quarter.
• Across five years, Assets topped out at $1.6 billion in Q1 2026 and bottomed at $587.8 million in Q4 2022.
• The 5-year median for Assets is $855.1 million (2024), against an average of $935.2 million.
• Across the five-year window, Assets retreated 17.34% in 2022 and soared 58.59% in 2024, its largest moves.
• Year by year, Assets stood at $587.8 million in 2022, then grew by 27.41% to $749.0 million in 2023, then surged by 58.59% to $1.2 billion in 2024, then jumped by 31.69% to $1.6 billion in 2025, then increased by 2.62% to $1.6 billion in 2026.
• Per Business Quant, the three latest ACAD Assets figures stand at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.3 billion (Q3 2025).